Table 1 Patient characteristics and treatment details

Age

 Median (range)

68 years (35–88)

Sex

 Male

35 (59%)

 Female

24 (41%)

Subtype

 Gastrointestinal NET

45 (76%)

 Pancreatic NET

8 (14%)

 Lung NET

2 (3%)

 Unspecified NET

2 (3%)

 Pancreatic NEC

1 (2%)

 Malignant pheochromocytoma

1 (2%)

‍Number of PRRT administrations per patient

 2

9 (15%)

 3

6 (10%)

 4

32 (52%)

 5

9 (15%)

 6

1 (2%)

 7

1 (2%)

 8

1 (2%)

Skeletal metastases

 Yes (proportion)

20/59 (34%)

 1 lesion

1

 2 lesions

4

 3 lesions

2

 4 lesions

0

   ≥ 5 lesions

13

Toxicity-related aborted treatment

 Yes (proportion)

7/59 (12%)

Previous PRRT

 Yes (proportion)

9/59 (15%)

 Delay since previous treatment—median (range)

36 months (5–96)

Tumour grade

 Grade 1

18 (31%)

 Grade 2

35 (59%)

 Grade 3

4 (7%)

 Unknown

2 (3%)